MX2019008260A - Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c. - Google Patents

Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.

Info

Publication number
MX2019008260A
MX2019008260A MX2019008260A MX2019008260A MX2019008260A MX 2019008260 A MX2019008260 A MX 2019008260A MX 2019008260 A MX2019008260 A MX 2019008260A MX 2019008260 A MX2019008260 A MX 2019008260A MX 2019008260 A MX2019008260 A MX 2019008260A
Authority
MX
Mexico
Prior art keywords
renal
compositions
methods
evaluation
treatment
Prior art date
Application number
MX2019008260A
Other languages
English (en)
Spanish (es)
Inventor
Mcpherson Paul
Patrick Kampf James
CHALFIN Donald
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2019008260A publication Critical patent/MX2019008260A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2019008260A 2017-01-12 2018-01-12 Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c. MX2019008260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762445692P 2017-01-12 2017-01-12
PCT/US2018/013561 WO2018132702A1 (en) 2017-01-12 2018-01-12 Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement

Publications (1)

Publication Number Publication Date
MX2019008260A true MX2019008260A (es) 2020-01-27

Family

ID=62840533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008260A MX2019008260A (es) 2017-01-12 2018-01-12 Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.

Country Status (8)

Country Link
US (2) US11353465B2 (https=)
EP (2) EP4063853A1 (https=)
JP (2) JP2020504157A (https=)
CN (2) CN110651187A (https=)
AU (1) AU2018207151B2 (https=)
CA (1) CA3049444A1 (https=)
MX (1) MX2019008260A (https=)
WO (1) WO2018132702A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4063853A1 (en) 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
CN114207436A (zh) * 2019-05-24 2022-03-18 机敏医药股份有限公司 基于c-c基序趋化因子配体14测量而评估和治疗肾损伤的方法
CA3145667A1 (en) * 2019-07-02 2021-01-07 Astute Medical, Inc Antibodies and assays for ccl14
EP4247395A4 (en) * 2020-11-18 2024-09-18 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure
CN113555122B (zh) * 2021-07-21 2024-04-26 中南大学湘雅二医院 一种重症脓毒症患者一过性和持续性aki的预测模型及其构建方法
CA3253529A1 (en) * 2022-03-03 2023-09-07 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR EVALUATING AND TREATING PERSISTENT ACUTE RENAL INJURY BASED ON A C-C MOTIFYING CHEMOKIN LIGAND MEASUREMENT 14

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU2003223172A1 (en) 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
EP1915614A4 (en) * 2005-07-21 2009-03-25 Univ Johns Hopkins METHOD FOR DETECTING AND TREATING AN ACUTE KIDNEY INJURY
EP2479569A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20110059537A1 (en) * 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
CA2740923A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462437A4 (en) 2009-08-07 2013-01-30 Rules Based Medicine Inc METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF
NZ600160A (en) 2009-11-07 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) * 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) 2010-06-23 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (https=) 2010-06-23 2015-05-22 Astute Medical Inc
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012136548A1 (en) 2011-04-04 2012-10-11 Universiteit Gent Biomarkers for acute kidney injury
PT2748605T (pt) 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
WO2013096740A1 (en) 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
CA2965153C (en) 2014-10-20 2023-10-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP4063853A1 (en) 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement

Also Published As

Publication number Publication date
AU2018207151A1 (en) 2019-07-18
CA3049444A1 (en) 2018-07-19
WO2018132702A1 (en) 2018-07-19
JP2020504157A (ja) 2020-02-06
EP4063853A1 (en) 2022-09-28
AU2018207151B2 (en) 2024-02-29
JP2022091846A (ja) 2022-06-21
CN110651187A (zh) 2020-01-03
EP3568695A1 (en) 2019-11-20
US20190339289A1 (en) 2019-11-07
US20230025225A1 (en) 2023-01-26
CN114088950A (zh) 2022-02-25
US11353465B2 (en) 2022-06-07
EP3568695A4 (en) 2020-12-16
US12203944B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016064877A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3070474A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2012001559A (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX2011008323A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
EP4582559A3 (en) Biomarkers of traumatic brain injury
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2585827A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP4299586A3 (en) Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
MX2014000283A (es) Metodos y composiciones para diagnóstico y pronóstico de lesión e insuficiencia renal.
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
MX2012003168A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal e insuficiencia renal.
MX2016009450A (es) Ensayo novedoso para detectar periostina humana.
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
GEP20257829B (en) Salivary biomarkers of brain injury
PH12018501813A1 (en) Early detection of hepatocellular carcinoma
WO2020115270A3 (en) Biomarker for detecting zearalenone effect